Rani Therapeutics is a clinical-stage biotech company that has developed a platform technology to enable oral delivery of biologic drugs.
Company profile
Ticker
RANI
Exchange
Website
CEO
Talat Imran
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
Rani Therapeutics, LLC ...
RANI stock data
Latest filings (excl ownership)
8-K
Submission of Matters to a Vote of Security Holders
30 May 24
10-Q
2024 Q1
Quarterly report
6 May 24
8-K
Rani Therapeutics Reports First Quarter 2024 Financial Results; Provides Corporate Update
6 May 24
ARS
2023 FY
Annual report to shareholders
17 Apr 24
DEFA14A
Additional proxy soliciting materials
17 Apr 24
DEF 14A
Definitive proxy
17 Apr 24
S-8
Registration of securities for employees
20 Mar 24
10-K
2023 FY
Annual report
20 Mar 24
8-K
Rani Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results; Provides Corporate Update
20 Mar 24
8-K
Rani Therapeutics Announces Positive Topline Results from Phase 1 Study of
5 Feb 24
Financial summary
Quarter (USD) | Mar 24 | Dec 23 | Sep 23 | Jun 23 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 23 | Dec 22 | Dec 21 | |
---|---|---|---|---|
Revenue | ||||
Cost of revenue | ||||
Operating income | ||||
Operating margin | ||||
Net income | ||||
Net profit margin | ||||
Cash on hand | ||||
Change in cash | ||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 7.38 mm | 7.38 mm | 7.38 mm | 7.38 mm | 7.38 mm | 7.38 mm |
Cash burn (monthly) | (no burn) | 1.01 mm | 4.68 mm | 5.42 mm | 3.13 mm | 4.04 mm |
Cash used (since last report) | n/a | 2.09 mm | 9.71 mm | 11.26 mm | 6.51 mm | 8.39 mm |
Cash remaining | n/a | 5.28 mm | -2.34 mm | -3.88 mm | 870.08 k | -1.01 mm |
Runway (months of cash) | n/a | 5.2 | -0.5 | -0.7 | 0.3 | -0.3 |
Institutional ownership, Q4 2023
13F holders | Current |
---|---|
Total holders | 7 |
Opened positions | 0 |
Closed positions | 31 |
Increased positions | 1 |
Reduced positions | 1 |
13F shares | Current |
---|---|
Total value | 293.68 mm |
Total shares | 26.47 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
South Lake One | 12.13 mm | $24.38 mm |
Quiroga Moreno Isidoro | 11.73 mm | $129.05 mm |
InCube Ventures II | 2.57 mm | $41.96 mm |
Prime Capital Investment Advisors | 16.68 k | $55.38 mm |
Activest Wealth Management | 9.80 k | $32.54 mm |
Cortes Isidoro Alfonso Quiroga | 8.40 k | $17.00 k |
Allworth Financial | 3.12 k | $10.36 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
29 May 24 | Andrew Farquharson | Stock Option Class A Common Stock | Grant | Acquire A | No | No | 5 | 50,000 | 250.00 k | 50,000 |
29 May 24 | Maulik Nanavaty | Stock Option Class A Common Stock | Grant | Acquire A | No | No | 5 | 50,000 | 250.00 k | 50,000 |
29 May 24 | Ausiello Dennis A | Stock Option Class A Common Stock | Grant | Acquire A | No | No | 5 | 50,000 | 250.00 k | 50,000 |
29 May 24 | Laureen Debuono | Stock Option Class A Common Stock | Grant | Acquire A | No | No | 5 | 50,000 | 250.00 k | 50,000 |
29 May 24 | Lisa Ann Rometty | Stock Option Class A Common Stock | Grant | Acquire A | No | No | 5 | 50,000 | 250.00 k | 50,000 |
News
BTIG Maintains Buy on Rani Therapeutics Hldgs, Raises Price Target to $14
9 May 24
Rani Therapeutics To Present Data On Oral Delivery Of An Ustekinumab Biosimilar Via The RaniPill Capsule At Digestive Disease Week 2024
9 May 24
HC Wainwright & Co. Maintains Buy on Rani Therapeutics Hldgs, Raises Price Target to $13
7 May 24
Rani Therapeutics Hldgs Q1 EPS $(0.29) Beats $(0.31) Estimate
6 May 24
Equifax Reports Weak Sales, Joins Synovus Financial And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
18 Apr 24